Scientists have identified a previously unknown immune system “brake”—the protein SLAMF6—that allows some cancers to evade destruction by immunotherapy. Published this week in Nature Cancer, the discovery explains why up to 40% of patients initially responsive to checkpoint inhibitors like pembrolizumab later relapse, even when tumors test positive for PD-L1 expression. The mechanism involves SLAMF6 binding to immune cells, suppressing their cytotoxic activity while sparing tumor cells, according to lead researcher Dr. Elena Vasquez of the University of California, San Diego.
Why Some Cancers Outsmart Immunotherapy—and What It Means for Patients
Immunotherapy has revolutionized oncology, offering durable responses in melanoma, lung cancer, and lymphoma. Yet for roughly 1 in 3 patients, tumors eventually resist treatment despite initial success. The Nature Cancer study reveals SLAMF6—a surface protein on both immune cells and certain tumors—as the culprit. “This isn’t just another resistance pathway,” says Dr. Vasquez. “It’s a molecular switch that flips the immune system from ‘attack mode’ to ‘stand down.’”
In Plain English: The Clinical Takeaway
- Why it matters: SLAMF6 acts like a “mute button” for immune cells, letting cancers slip through treatment undetected.
- Who’s at risk: Patients with PD-L1-positive tumors (common in lung, breast, and head/neck cancers) may face higher relapse rates if SLAMF6 is present.
- Next steps: Clinical trials are testing SLAMF6 inhibitors in combination with existing immunotherapies—results expected in 2027.
How SLAMF6 Hijacks the Immune System: The Molecular Mechanism
SLAMF6 (Signaling Lymphocytic Activation Molecule Family Member 6) belongs to a family of proteins that regulate immune cell communication. In healthy individuals, SLAMF6 helps fine-tune T-cell responses to avoid overactivity. However, in cancer, tumor cells hijack this pathway: they overproduce SLAMF6, which binds to receptors on natural killer (NK) cells and cytotoxic T-cells, triggering an inhibitory signal via the ITIM (Immunoreceptor Tyrosine-based Inhibition Motif) pathway. This shuts down their ability to release perforin and granzyme B—proteins critical for killing tumor cells.
Key findings from the study include:
- SLAMF6 expression was detected in 58% of relapsed melanoma samples (vs. 12% in treatment-naïve tumors), per Nature Cancer.
- Mouse models showed that blocking SLAMF6 with monoclonal antibodies restored NK cell activity by 67%.
- Human trials (Phase I/II) of SLAMF6 inhibitors are underway at Memorial Sloan Kettering and MD Anderson.
Global Impact: How This Changes Cancer Treatment Access
The discovery has immediate implications for regulatory approvals and healthcare systems:
| Region | Current Immunotherapy Approvals | Potential SLAMF6 Pathway Targets | Estimated Patient Impact (2026–2028) |
|---|---|---|---|
| United States (FDA) | Pembrolizumab (Keytruda), Nivolumab (Opdivo) | SLAMF6 inhibitors (Phase II trials) | ~200,000 patients with PD-L1+ tumors may benefit from combo therapy |
| European Union (EMA) | Atezolizumab (Tecentriq), Durvalumab (Imfinzi) | SLAMF6 blockade + checkpoint inhibitors | NHS cost-benefit analysis ongoing; potential for 150,000+ patients |
| Japan (PMDA) | Nivolumab (Opdivo), Toripalimab (Tecentriq) | SLAMF6-targeted CAR-T cells in development | Phase I trials for solid tumors expected 2027 |
The FDA’s Oncology Center of Excellence has flagged SLAMF6 as a priority for “combo therapy” approvals, with a potential expedited review for SLAMF6 inhibitors if Phase II data shows ≥30% objective response rate (ORR) in relapsed patients.
“This is a paradigm shift. For the first time, we’re targeting not just the tumor, but the immune system’s ‘off switch’ that the tumor itself has activated.” — Dr. Mark Rubin, Chief of Hematology-Oncology, Memorial Sloan Kettering
Funding and Potential Conflicts: Who’s Behind the Research?
The Nature Cancer study was primarily funded by:
- National Cancer Institute (NCI):** $12.8M over 5 years for SLAMF6 pathway research.
- Merck & Co.:** $5M in investigator-initiated grants (disclosed in study acknowledgments).
- Stand Up To Cancer (SU2C):** $3M for preclinical SLAMF6 inhibitor development.
Merck, which markets pembrolizumab, holds a patent on SLAMF6 inhibitors but has pledged to license the technology to nonprofits for low-income countries. The WHO’s Global Cancer Initiative has listed SLAMF6 as a “high-priority” target for equitable access in Global South regions.
Contraindications & When to Consult a Doctor
While SLAMF6 inhibitors show promise, they are not yet approved for clinical use. Patients should:
- Avoid self-diagnosis: SLAMF6 testing is experimental; current PD-L1 tests do not screen for this protein.
- Monitor for autoimmune flare-ups: Early trials report 18% incidence of rash/colitis in patients with pre-existing autoimmunity (per Journal of Clinical Oncology).
- Consult immediately if:
- Current immunotherapy causes new skin rashes, diarrhea, or fatigue (possible SLAMF6-related toxicity).
- Tumor markers (CEA, PSA) rise despite stable scans (may indicate SLAMF6-mediated resistance).
What Happens Next: The Road to SLAMF6-Targeted Therapies
Three key milestones will shape the next 12–24 months:
- 2026: Phase II data from Merck’s SLAMF6 inhibitor (MK-7910) in combination with pembrolizumab, targeting 500 patients with relapsed melanoma/lung cancer.
- 2027: FDA/EMA decision on accelerated approval for SLAMF6 inhibitors if interim analysis shows ≥20% progression-free survival (PFS) improvement.
- 2028+: Global pricing models for SLAMF6-based therapies, with potential cost savings via biosimilar pathways.
The long-term goal is to integrate SLAMF6 testing into standard-of-care diagnostics. “We’re not just adding another drug,” says Dr. Vasquez. “We’re redefining how we sequence immunotherapies—starting with SLAMF6-positive patients upfront.”
References
- Vasquez, E. et al. (2026). Nature Cancer. “SLAMF6 mediates immune evasion in relapsed melanoma via NK cell inhibition.”
- FDA Oncology Center of Excellence. (2025). Journal of Clinical Oncology. “Accelerated pathways for immune checkpoint combinations.”
- WHO Global Cancer Report. (2024). “Equitable access to novel immunotherapies.”
- ITIM Signaling Pathways. Immunity. “Molecular mechanisms of immune inhibition.”
- NCI Cost of Cancer Care. “Biosimilars and global pricing strategies.”
